Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Chronic Thromboembolic Pulmonary Hypertension. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-000347-14 Sponsor Protocol Number: PROCLAIM Start Date*: 2016-06-16
    Sponsor Name:IDIBAPS
    Full Title: Cell proliferation in pulmonary hypertension: mollecular imaging detection by FDG PET. Comparative study between patients and healthy subjects
    Medical condition: Pulmonary artery hypertension and thromboembolic chronic pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10037405 Pulmonary hypertension primary LLT
    19.0 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002950-56 Sponsor Protocol Number: AC-055E201 Start Date*: 2014-02-20
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chron...
    Medical condition: Inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) AT (Completed) BE (Completed) GB (Completed) HU (Completed) NL (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017155-10 Sponsor Protocol Number: 10-aifa-2005-01 Start Date*: 2006-11-07
    Sponsor Name:CASA DI CURA PRIVATA S.RAFFAELE - PISANA
    Full Title: Evaluation of tolerability and efficacy of the combination Sildenafil/Bosentan in patients with severe pulmonary hypertension.
    Medical condition: severe pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003457-25 Sponsor Protocol Number: AC-055E202 Start Date*: 2014-06-13
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Long term, multicenter, single-arm, open-label extension study of the MERIT-1 study, to assess the safety, tolerability and efficacy of macitentan in subjects with inoperable chronic thromboembolic...
    Medical condition: Inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) AT (Completed) NL (Completed) LT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003934-10 Sponsor Protocol Number: AC-055-314 Start Date*: 2018-03-19
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: mUlticenter, single-arM, open-laBel, long-teRm safety study with macitEntan in patients with puLmonary arterial hypertension previousLy treated with mAcitentan in clinical studies
    Medical condition: Pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004131-24 Sponsor Protocol Number: 67896062CTP3001 Start Date*: 2020-05-29
    Sponsor Name:ACTELION Pharmaceuticals Ltd.
    Full Title: A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in ino...
    Medical condition: Chronic thromboembolic pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) ES (Prematurely Ended) AT (Completed) SK (Completed) LT (Completed) FR (Completed) IT (Prematurely Ended) PT (Prematurely Ended) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003539-19 Sponsor Protocol Number: BAY63-2521/11349 Start Date*: 2008-11-26
    Sponsor Name:Bayer HealthCare AG,
    Full Title: Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmo...
    Medical condition: Chronic Thromboembolic Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed) AT (Completed) IT (Completed) IE (Prematurely Ended) ES (Completed) BE (Completed) CZ (Completed) PT (Completed) DK (Completed) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002823-41 Sponsor Protocol Number: AC-065B302 Start Date*: 2019-06-03
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipa...
    Medical condition: Chronic Thromboembolic Pulmonary Hypertension, inoperable or persistent/recurrent
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) BE (Completed) NL (Completed) HU (Completed) AT (Completed) BG (Completed) DK (Prematurely Ended) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002104-40 Sponsor Protocol Number: BAY63-2521/16097 Start Date*: 2013-03-14
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting PH after surgical treatment who are not satisfactorily treated and cannot participate in ...
    Medical condition: Chronic Trombo Embolic Pulmonary Hypertention
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10068740 CTEPH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) PT (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) NL (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000072-16 Sponsor Protocol Number: BAY63-2521/11348 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic...
    Medical condition: Chronic Thromboembolic Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) GB (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) IT (Completed) BE (Completed) CZ (Completed) SK (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002788-80 Sponsor Protocol Number: Uni-Koeln-4243 Start Date*: 2020-09-09
    Sponsor Name:University of Cologne
    Full Title: An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH) (MPO-PAH)
    Medical condition: Group 1: Pulmonary arterial hypertension (PAH) Group 2: Postcapillary pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006787-25 Sponsor Protocol Number: 16122021 Start Date*: 2022-07-06
    Sponsor Name:Rigshospitalet The Heart Center
    Full Title: Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial
    Medical condition: Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10065150 Associated with pulmonary arterial hypertension LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10065151 Idiopathic pulmonary arterial hypertension LLT
    24.1 10010331 - Congenital, familial and genetic disorders 10085244 Heritable pulmonary arterial hypertension PT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10068740 CTEPH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005462-34 Sponsor Protocol Number: 202006RCT Start Date*: 2021-06-23
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Medical condition: Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001387-39 Sponsor Protocol Number: 1.4 Start Date*: 2019-03-15
    Sponsor Name:Thoraxklinik-Heidelberg gGmbH
    Full Title: A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial h...
    Medical condition: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005885-30 Sponsor Protocol Number: B1321001 Start Date*: 2010-01-12
    Sponsor Name:Pfizer Ltd
    Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001646-18 Sponsor Protocol Number: AMB115811 Start Date*: 2013-04-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) AT (Completed) DE (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001642-17 Sponsor Protocol Number: AMB116457 Start Date*: 2013-04-26
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001965-33 Sponsor Protocol Number: AC-052-366 Start Date*: 2005-11-01
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of bosentan in patients with inoperable chronic thromboe...
    Medical condition: Inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037436 Pulmonary thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004793-17 Sponsor Protocol Number: 402-C-1302 Start Date*: 2017-05-03
    Sponsor Name:Reata Pharmaceuticals, Inc.
    Full Title: A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension
    Medical condition: Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002900-40 Sponsor Protocol Number: AC-052-370 Start Date*: 2005-08-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: BENEFIT-OL / Long-term open-label extension study in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) who completed protocol AC-052-366/BENEFIT
    Medical condition: Inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) ES (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA